Lilly opens state-of-the-art research and development center in the Boston Seaport
On August 13, New England Council member Eli Lilly and Company announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to furthering the company’s efforts in RNA and DNA-based therapies and discovering new drug targets to create transformative medicines for a range of conditions.
Lilly is a medicine company that aims to utilize innovative biotechnology and medicine to create solutions to major health challenges and work toward achieving a healthier world. The new site will house the first Lilly Gateway Labs location on the East Coast, encouraging a culture of shared expertise and real-time learning to promote the development of novel medicines.
“The opening of LSC expands upon Lilly’s long-standing presence in the Boston area,” said Daniel Skovronsky, M.D., Ph.D., chief scientific officer and president, Lilly Research Laboratories, president, Lilly Immunology. “We are committed to being supportive neighbors in this hub of discovery and innovation, furthering collaborating with leading institutions and new talent to continue delivering transformative medicines for the people who need them the most.”
The New England Council congratulates Lilly on expanding its sites to foster the development of life-changing scientific visions.
Read more on Lilly’s website.